The Pill That Could Change Weight Loss: FDA Approves First Oral Wegovy

The U.S. Food and Drug Administration has approved the first oral GLP-1 (glucagon-like peptide-1) medication for weight loss, marking a pivotal moment for the millions of Americans who want effective weight management without weekly injections. Novo Nordisk's oral Wegovy pill will be available in pharmacies starting January 2025, with a starting price of $149 per month for cash-paying patients.

How Effective Is the Oral Wegovy Pill?

Clinical trials involving over 300 participants showed impressive results for the oral version. People taking the highest dose of 25 milligrams daily lost an average of 16.6% of their body weight over 64 weeks, compared to just 2.7% for those on placebo. This matches closely with the injectable Wegovy, which showed up to 17.4% weight reduction in its key trials.

The pill works by mimicking the same gut hormone as the injection, slowing stomach emptying and making people feel fuller longer. "We believe it will expand access and options for patients," Dr. Jason Brett, principal U.S. medical head for Novo Nordisk, told CNN. "We know there are some patients who just won't take an injectable medication."

What Are the Key Differences Between Pills and Injections?

While both forms contain semaglutide, the oral version comes with specific requirements that patients need to understand:

• Timing Restrictions: The pill must be taken on an empty stomach with only a small amount of water, and patients cannot eat, drink, or take other medications for 30 minutes afterward
• Higher Doses Required: Oral doses range from 1.5 mg to 25 mg daily, much higher than the 2.4 mg weekly injection, because pills are broken down in the stomach rather than entering the bloodstream directly
• Storage Benefits: Unlike injections that require refrigeration between 36-46°F, the pills don't need special storage conditions
• Cost Structure: While the starting dose costs $149 monthly, higher effective doses will likely cost significantly more, though exact prices haven't been disclosed yet

Side effects mirror those of the injectable version, with gastrointestinal issues like nausea, diarrhea, and vomiting being most common. About 7% of participants in the pill trial stopped treatment due to side effects, compared to 6% on placebo.

Who Should Consider the Oral Option?

The oral Wegovy is approved for adults with obesity (body mass index of 30 or higher) or those who are overweight with weight-related health conditions. It's also cleared to reduce cardiovascular risks like heart attack and stroke in people with obesity and established heart disease.

"As we start seeing these benefits, like for people who've had cardiac disease, 20% reduction in death or another event; reduction in sleep apnea; reduction in heart failure; improved liver function, that's, to me, the exciting part," said Dr. Judith Korner, an endocrinologist and director of the Metabolic and Weight Control Center at Columbia University.

This approval gives Novo Nordisk a head start over competitor Eli Lilly, whose oral GLP-1 drug orforglipron is expected to receive FDA approval by March 2026. Lilly's pill showed 11% weight loss over 72 weeks and can be taken at any time without food restrictions, potentially offering more convenience.

With about 1 in 8 U.S. adults currently taking GLP-1 medications, the availability of pill options could significantly expand access to these treatments, especially for people uncomfortable with injections or those seeking more affordable alternatives to the current injectable options.